These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11711259)

  • 1. Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid.
    Sambatakou H; Giamarellos-Bourboulis EJ; Galanakis N; Giamarellou H
    Int J Antimicrob Agents; 2001 Nov; 18(5):441-4. PubMed ID: 11711259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
    Cardey J; Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Fourtillan JP; Beauchant M
    Eur J Clin Pharmacol; 1987; 33(5):469-72. PubMed ID: 3480805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of fluoroquinolones in hepatic failure.
    Montay G; Gaillot J
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():61-7. PubMed ID: 2258353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low ascitic fluid total protein levels is not associated to the development of spontaneous bacterial peritonitis in a cohort of 274 patients with cirrhosis.
    Mo S; Bendtsen F; Wiese SS; Kimer N
    Scand J Gastroenterol; 2018 Feb; 53(2):200-205. PubMed ID: 29214880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis.
    Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Beauchant M
    Eur J Clin Pharmacol; 1989; 37(3):261-5. PubMed ID: 2612541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of anxiogenic effects of fluoroquinolones in rats.
    Prabhu S; Rewari S
    Indian J Physiol Pharmacol; 1998 Jan; 42(1):135-8. PubMed ID: 9513807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
    Varela JE; Cohn SM; Brown M; Ward CG; Namias N; Spalding PB
    J Antimicrob Chemother; 2000 Mar; 45(3):337-42. PubMed ID: 10702553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Excretion of fluoroquinolones into saliva].
    Kelentey BA; Kelentey BJ; Fekete I; Kozma J
    Fogorv Sz; 1995 Sep; 88(9):293-7. PubMed ID: 8522025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis.
    Tuncer I; Topcu N; Durmus A; Turkdogan MK
    Hepatogastroenterology; 2003; 50(53):1426-30. PubMed ID: 14571754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
    J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved penetration of aminoglycosides and fluorozuinolones into the aqueous humour of patients by means of Acuvue contact lenses.
    Hehl EM; Beck R; Luthard K; Guthoff R; Drewelow B
    Eur J Clin Pharmacol; 1999 Jun; 55(4):317-23. PubMed ID: 10424326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and tissue penetration of the fluoroquinolones.
    Bergeron MG
    Clin Invest Med; 1989 Feb; 12(1):20-7. PubMed ID: 2920479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of single-dose intravenous ciprofloxacin in blood and ascites of patients with pelvic peritonitis.
    Mikamo H; Ninomiya M; Tamaya T
    J Infect Chemother; 2003 Sep; 9(3):276-7. PubMed ID: 14513401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary pharmacodynamics of low-dose ciprofloxacin and ofloxacin.
    Stein GE; Schooley S; McMillan J
    Diagn Microbiol Infect Dis; 1998 Apr; 30(4):261-5. PubMed ID: 9582586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of three newer quinolones in pregnant and lactating women.
    Giamarellou H; Kolokythas E; Petrikkos G; Gazis J; Aravantinos D; Sfikakis P
    Am J Med; 1989 Nov; 87(5A):49S-51S. PubMed ID: 2589384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats.
    Kastner M; Rahm U; Baumann-Wilschke I; Bello A; Stahlmann R
    Arch Toxicol; 2004 Feb; 78(2):61-7. PubMed ID: 14661070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.